Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

Athenex (NASDAQ: ATNX), a biopharmaceutical company focused on cancer therapies, will participate in the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022. Management, including CEO Dr. Johnson Lau and President Dr. Dan Lang, will engage in a fireside chat on November 30 at 3:05 PM ET. Additionally, they will hold one-on-one investor meetings, available upon scheduling through Evercore ISI representatives. Athenex aims to advance next-generation cell therapy and improve cancer treatment outcomes.

BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in the 5^th Annual Evercore ISI HealthCONx Conference, taking place virtually November 29 to December 1, 2022.

Dr. Johnson Lau, Chief Executive Officer of Athenex, and Dr. Dan Lang, President of Athenex Cell Therapy, will be participating in a fireside chat on Wednesday, November 30, 2022, beginning at 3:05pm Eastern Time. Athenex management will also be available for one-on-one investor meetings during the event. Please contact your representative at Evercore ISI to schedule a virtual one-on-one meeting with management during the conference.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Cell therapy, based on NKT cells and (2) Orascovery, based on a P-glycoprotein inhibitor. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible, and tolerable treatments. For more information, please visit www.athenex.com.

Athenex Contacts

Daniel Lang, M.D.
Athenex, Inc.
Email: danlang@athenex.com

Tim McCarthy
LifeSci Advisors, LLC
Email: tim@lifesciadvisors.com

FAQ

When will Athenex participate in the Evercore ISI HealthCONx Conference?

Athenex will participate in the conference from November 29 to December 1, 2022.

Who from Athenex will speak at the conference?

Dr. Johnson Lau, CEO, and Dr. Dan Lang, President of Athenex Cell Therapy, will participate in a fireside chat.

What time is Athenex's fireside chat during the conference?

The fireside chat will take place on November 30, 2022, at 3:05 PM Eastern Time.

How can investors meet with Athenex management at the conference?

Investors can schedule one-on-one meetings with Athenex management through their representatives at Evercore ISI.

What is Athenex's focus in biopharmaceutical development?

Athenex focuses on the discovery, development, and commercialization of novel cancer therapies.